Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer

OBJECTIVES: A small subset of patients treated with immune checkpoint inhibitors manifest atypical patterns of response, the so-called pseudoprogression (PP) and hyperprogression (HP). Their prevalence in urothelial (UC) and renal cancer (RCC) remains, to date, mostly uninvestigated. Therefore, we a...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:World J Urol
Hlavní autoři: Soria, Francesco, Beleni, Andrea I., D’Andrea, David, Resch, Irene, Gust, Kilian M., Gontero, Paolo, Shariat, Shahrokh F.
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer Berlin Heidelberg 2018
Témata:
Topic Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6208670/
https://ncbi.nlm.nih.gov/pubmed/29549485
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00345-018-2264-0
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky